Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, March 28, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for clearing human papillomavirus-driven pre-cancerous cervical lesions, today announced that they will present interim Phase 1 clinical data for PRTX007, a novel, orally administered, small molecule […] The post Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting appeared first on Primmune .